At least one sponsor is getting ahead of possible new FDA restrictions on use of opioid-containing antitussants to treat pediatric cough.
If FDA agrees with UCB SA's request to contraindicate its Tussionnex (hydrocodone/chlorpheniramine) for patients under 18 years of age,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?